KBP Biosciences
13
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.7%
1 terminated/withdrawn out of 13 trials
92.3%
+5.8% vs industry average
8%
1 trials in Phase 3/4
17%
2 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
Role: lead
Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease
Role: lead
Mass Balance Study of KBP-5074 in Healthy Male Subjects
Role: lead
Bioavailability of KBP-5074 Tablet vs Capsule Formulations
Role: lead
Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment
Role: lead
Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074
Role: lead
Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects
Role: lead
Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment
Role: lead
Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
Role: lead
Safety, Tolerability and Pharmacokinetics of KBP-7072
Role: lead
Study of KBP-7072 in Healthy Male and Female Subjects
Role: lead
A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects
Role: lead
A Multiple Ascending Dose Study of KBP-7072 in Healthy Subjects
Role: lead
All 13 trials loaded